Xcout IntelLongeveron Inc. competitors & alternatives
The 12 closest competitors and alternatives to Longeveron Inc. among biotechnology companies — ranked by similarity to what Longeveron Inc. actually does, not by market-cap band.
Subscribe to see Longeveron Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Longeveron Inc.
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Longeveron Inc. at a glance
Longeveron Inc. is a biotechnology company headquartered in Miami, United States. It is publicly listed (LGVN) with a market capitalisation of $7.8M. Xcout tracks 36 named people at Longeveron Inc., including Stephen H Willard (Chief Executive Officer & Director).
Longeveron Inc. leadership
- Stephen H WillardChief Executive Officer & Director
- Lisa A. LocklearChief Financial Officer
- Nirav Suresh JhaveriCFO and Principal Financial & Accounting Officer
- Devin BlassChief Technology Officer & Senior Vice President of Chemistry, Manufacturing, and Controls
- Joshua M. HareExecutive Chairman and Chief Science Officer
- Nataliya AgafonovaChief Medical Officer
30 more named people on record for Longeveron Inc., with roles, board committees and tenure — see the full roster →
Top 12 Longeveron Inc. competitors
Ranked by semantic similarity — how close each company is to Longeveron Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
Rejuveron Life Sciences AG is a biotechnology company headquartered in Schlieren, Switzerland, focused on developing innovative therapeutics and therapies for aging-related diseases and longevity.
Similar biotechnology company
Aegle Therapeutics Corp. is a clinical-stage biotechnology company headquartered in Miami, Florida, with additional operations in Woburn, Massachusetts. The company is a leader in developing novel extracellular vesicle therapies to treat various diseases and disorders.
Biotech
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Biotech
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Biotech
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company specializing in developing biological therapeutics aimed at treating degenerative diseases and fostering regenerative medicine. Its flagship investigational product, Zofin, is an acellular biologic therapy sourced from perinatal materials. This candidate is currently in Phase I/II clinical trials, evaluating its efficacy for COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis. The company's portfolio also includes Patient Pure X, an autologous, blood-derived biologic technology designed to enhance the body's natural capacity to reduce cellular inflammation and promote tissue healing. Furthermore, Zeo ScientifiX develops and distributes products containing its proprietary ingredients for topical aesthetic applications. These offerings include ZEO GROW X, a professional-grade formula delivering concentrated topical exosomes to support follicular function, as well as ZEO GROW BOOST and EXO FOLLICLE FUEL. Founded in 2011, the company was formerly known as Organicell Regenerative Medicine, Inc. before rebranding to Zeo ScientifiX, Inc. in February 2024. It is headquartered in Davie, Florida.
Biotech
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Biotech
Sernova Corp. is a Canadian firm, established in 1998 and headquartered in London, that specializes in advanced regenerative medicine therapeutics and is currently in its clinical development phase. The company's primary objective is to innovate and bring to market novel treatments, with a core focus on its unique "Cell Pouch" system. This sophisticated medical device is engineered to create a highly vascularized environment within the body, enabling the successful implantation and integration of therapeutic cells. Once integrated, these cells are designed to continuously release vital proteins or hormones, providing a long-term approach to managing debilitating chronic conditions like diabetes, hemophilia, and thyroid disease. Accompanying the Cell Pouch are related technologies that involve specialized therapeutic cells and methods to shield them from the body's immune response. Sernova actively collaborates with AgeX Therapeutics, Inc. to develop immune-protected therapeutic cells and maintains a research partnership with the University of Miami to further refine its Cell Pouch cell therapy platform.
Biotech
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Biotech
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Biotech
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Similar biotechnology company
Novoron Bioscience, Inc. is a San Diego-based biotechnology company developing novel therapeutics to address central nervous system and other conditions.
Biotech
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Longeveron Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Longeveron Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →